Shopping Cart
- Remove All
Your shopping cart is currently empty
AUDA
AUDA is an inhibitor of sEH(IC50 values of 18 and 69 nM for the mouse and human enzymes, respectively)
Catalog No. T7898Cas No. 479413-70-2
Select Batch
Purity:≥95%
Contact us for more batch information
AUDA
Catalog No. T7898Cas No. 479413-70-2
AUDA is an inhibitor of sEH(IC50 values of 18 and 69 nM for the mouse and human enzymes, respectively)
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | $44 | In Stock | |
| 25 mg | $80 | In Stock | |
| 50 mg | $129 | In Stock | |
| 100 mg | $208 | In Stock | |
| 200 mg | $329 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $48 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "AUDA"
1,3-Diphenylurea
T2716102-07-8
1, 3-Diphenylurea is involved with Epoxide hydrolase activity.
- $29
Size
QTY
Valpromide
Valpramide, Dipropylacetamide, Depamide, 2-propylpentanamide
T03552430-27-5
Valpromide (Dipropylacetamide) is a carboxamide derivative of valproic acid, used in the treatment of epilepsy and some affective disorders.
- $30
Size
QTY
N,N'-Dicyclohexylurea
NSC 17013, Dicyclohexylurea, Dicyclohexylcarbodiamide, DCU, AURORA KA-3582, 1,3-Dicyclohexylurea
T230442387-23-7
N,N'-Dicyclohexylurea (AURORA KA-3582) is a soluble epoxide hydrolase (sEH) inhibitor.
- $29
Size
QTY
CUDA
T10900479413-68-8
CUDA is an effective soluble cyclohydrolase inhibitor with IC50 of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases the activity of peroxisome proliferator-activated receptor (PPAR) alpha. CUDA may be valuable for the study of cardiovascular diseases.
- $39
Size
QTY
(Rac)-EC5026
Urea, N-[3-fluoro-4-(trifluoromethoxy)phenyl]-N'-[1-(2-methyl-1-oxobutyl)-4-piperidinyl]-
T98321809885-55-9In house
(Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) with a Ki of 0.06 nM, useful for research on Parkinson's disease and dementia with Lewy Bodies (DLB) [1].
- $58
Size
QTY
Dual FAAH/sEH-IN-1
T635362756099-59-7In house
Dual FAAH/sEH-IN-1 is a dual inhibitor of sEH (soluble epoxide hydrolase) (IC50: 9.6 nM) and FAAH (fatty acid amide hydrolase) (IC50: 7 nM) with high affinity and anti-inflammatory activity.
- $238
Size
QTY
EC5026
BPN-19186
T111471809885-32-2In house
EC5026 (BPN-19186) has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators.
- $30
Size
QTY
CAY10640
sEH inhibitor-1
T383671208549-68-1
CAY10640 (sEH inhibitor-1) is a potent, orally active, water-soluble epoxide hydrolase (sEH) inhibitor that inhibits sEH in humans and mice with IC50s of 0.4 and 5.3 nM, respectively.
- $178
Size
QTY
sEH inhibitor-3
7-MPN
T624251809885-35-5
sEH inhibitor-3 (compound 35) is a potent, orally active inhibitor of soluble epoxide hydrolase (sEH), acting on human sEH with a Ki of 0.75 nM.
- $293
Size
QTY
VU534
T77594923509-20-0
VU534 is a NAPE-PLD agonist with an EC50 of 0.30 μM.VU534 is a dual inhibitor of FAAH and sEH, with an IC50 of 1.2 μM for sEH.VU534 is used in diseases related to cardiometabolism.
- $36
Size
QTY
GSK2256294A
GSK 2256294
T154301142090-23-0
GSK2256294A (GSK 2256294) is potent, selective inhibitor of recombinant human, rat and mouse sEH with IC50 of 27 pM, 61 pM and 189 pM, respectively.
- $58
Size
QTY
Diflapolin
T8844724453-98-9
Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP) and soluble epoxide hydrolase (sEH) inhibitor, exhibiting marked anti-inflammatory efficacy and high target selectivity.
- $38
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
| Description | AUDA is an inhibitor of sEH(IC50 values of 18 and 69 nM for the mouse and human enzymes, respectively) |
| Targets&IC50 | sEH:18 nM (mouse), sEH:69 nM (human) |
| In vitro | AUDA significantly inhibited PDGF-induced rat VSMC proliferation, which coincided with Pin1 suppression and heme oxygenase-1 (HO-1) upregulation.?However, exogenous 8,9-EET, 11,12-EET, and 14,15-EET treatments did not alter Pin1 or HO-1 levels and had little effect on the proliferation of rat VSMCs.?On the other hand, AUDA enhanced the PDGF-stimulated cell migration of rat VSMCs.?Furthermore, AUDA-induced activation of cyclooxygenase-2 (COX-2) and subsequent thromboxane A2 (TXA?) production were required for the enhanced migration[1]. |
| In vivo | AUDA increased the proliferation, migration, adhesion and tube formation ability of HCAECs in a dose-dependent manner.?Furthermore, in the mouse model of KD, AUDA reduced the protein expression of MMP-9, IL-1β and TNF-α, indicating that AUDA may alleviate inflammatory reactions in the coronary arteries of KD model mice[2]. |
| Cell Research | Cell Line:Vascular smooth muscle cell (VSMC).Concentration:0.3, 1, 3, 10 μg/mL. Incubation Time:48 hours[1] |
| Animal Research | AUDA (i.p.; 10 mg/kg; 14 days) reduces TNF-α, MMP-9 and IL-1β expression levels.Animal Model:Male (wild-type). C57BL/6 mice (age, 4-6 weeks; weight, 18-20 g).Dosage:10 mg/kg.Administration:i.p.; 14 days[2] |
| Molecular Weight | 392.58 |
| Formula | C23H40N2O3 |
| Cas No. | 479413-70-2 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 30 mg/ml (76.41 mM)  | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy AUDA | purchase AUDA | AUDA cost | order AUDA | AUDA chemical structure | AUDA in vivo | AUDA in vitro | AUDA formula | AUDA molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.